Skip to main content
SpringerLink
Log in

Update on Biosimilars in Asia

  • Biosimilars (E Mysler, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review provides an update on the evolution of, manufacturing of, and regulations for biosimilars in Asian countries.

Recent Findings

The use of biologics revolutionized the treatment of various diseases. However, the high cost of biologics remained unaffordable for most Asian patients and increases the financial burden of Asian governments. The development of biosimilars provides the best solution for this predicament. A great boom of biosimilars is developing in Asia. Hundreds of biopharmaceutical companies have established their manufacturing facilities and provide affordable products for Asian patients. Regulation guidelines and international harmonization are evolving.

Summary

Better manufacturing quality and post-market pharmacovigilance are needed in Asia despite the rapid evolution of biosimilar development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Recently published papers of particular interest have been highlighted as: • Of importance

  1. Kim EY, Moudgil KD. Immunomodulation of autoimmune arthritis by pro-inflammatory cytokines. Cytokine. 2017; doi:10.1016/j.cyto.2017.04.012.

  2. Schinnerling K, Aguillón JC, Catalán D, Soto L. The role of interleukin-6 signaling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis. Clin Exp Immunol. 2017; doi:10.1111/cei.12966.

  3. Scheinberg MA, Azevedo VF. Biosimilars in rheumatology: perspective and concerns. Rheumatology (Oxford). 2014;53(3):389–90.

    Article  Google Scholar 

  4. Top 50 pharmaceutical products by global sales. http://www.pmlive.com/top_pharma_list/Top_50_pharmaceutical_products_by_global_sales (accessed 22/Apr/2017).

  5. The brave new world of biosimilars. https://www.futurereadysingapore.com/2017/the-brave-new-world-of-biosimilars.html (accessed 22/Apr/2017).

  6. • Bas TG, Oliu Castillo C. Biosimilars in developed and developing east and Southeast Asian countries: Japan, South Korea, and Malaysia—overview, evolution, and regulations assessment. Biomed Res Int. 2016(5910403):12. This article describes the unmet need for better treatment in Asian countries, and it further illustrates the evolution and regulation of biosimialr manufacturing industry in these countries

  7. • Al-Sabbagh A, Olech E, McClellan JE, Kirchhoff CF. Development of biosimilars. Semin arthritis rheum. 2016 45(5 Suppl):S11–S18. This article illustrates the manufacturing process and quality control for biosimialr products, the comprehensive description details and the tight control of each manufacturing process for biosimilar products.

  8. Blandizzi C, Meroni PL, Lapadula G. Comparing originator biologics and biosimilars: a review of the relevant issues. ClinTher. 2017; doi:10.1016/j.clinthera.2017.03.014.

  9. Markenson J, Alvarez DF, Jacobs I, Kirchhoff C. A practical guide about biosimilar data for health care providers treating inflammatory diseases. Biologics. 2017;11:13–21.

    PubMed  PubMed Central  Google Scholar 

  10. Clinicaltrials.gov. http://clinicaltrials.gov (accessed 22/Apr/2017).

  11. http://www.pharmachinaonline.com (Accessed 22/Apr/2017).

  12. China FDA. http://eng.sfda.gov.cn/WS03/CL0755/search.html?columnid=WID|CTITLE|CONTENT&relation=MUST|SHOULD|SHOULD&tableName=Region&colNum=3&qryNum=3&curPage=1&qryidstr=wid|qry1|qry1&qryValue=ws03|biosimilars|biosimilars (accessed 22/Apr/2017).

  13. Christl LA, Woodcock J, Kozlowski S. Biosimilars: the US regulatory framework. Annu Rev Med. 2017;68:243–54.

    Article  CAS  PubMed  Google Scholar 

  14. EMAguideline on similar biological medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf (accessed 25/Apr/2017).

  15. • Declerck P, Danesi R, Petersel D, Jacobs I. The language of biosimilars: Clarification, definitions, and regulatory aspects. Drugs. 2017;77:671–7. This paper provides clear definition of terms used for the description of biologic products

    Article  PubMed  PubMed Central  Google Scholar 

  16. Rathore AS. Biosimilars in India. J Proteome. 2015;127:71–2.

    Article  CAS  Google Scholar 

  17. Guidelines on similar biologics: regulatory requirements for marketing authorization in India. http://www.cdsco.nic.in/writereaddata/Bio%20Similar%20Guideline.pdf (accessed 25/Apr/2017).

  18. Biosimilars approved in Japan Oct 2016 update. http://gabionline.net/Biosimilars/General/Biosimilars-approved-in-Japan (accessed 25/Apr/2017).

  19. Arato T. Japanese regulation of biosimilar products: past experience and current challenges. Br J ClinPharmacol. 2016;82(1):30–40.

    Google Scholar 

  20. Naqasaki M, Ando Y. Clinical development and trial design of biosimilar products: a Japanese perspective. J Biopharm J Biopharm Stat. 2014;24(6):1165–72.

    Article  Google Scholar 

  21. Derbyshire M. Biosimilar development and regulation in Japan. Generics and Biosimilars Initiative Journal (GaBI Journal). 2013;2(4):207–8.

    Article  Google Scholar 

  22. Biosimilars approved in South Korea 2016 update. http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-South-Korea (accessed 25/Apr/2017).

  23. Korean guidelines on the evaluation of biosimilar products. http://www.kfda.go.kr/index.kfda?mid-226&pageNo-1&seq-388&cmd-v; July 2009 (accessed 26/Apr/2017).

  24. Suh SK, Park Y. Regulatory guideline for biosimilar products in Korea. Biologicals. 2011;39:336–8.

    Article  PubMed  Google Scholar 

  25. https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=241607919 (accessed 26/Apr/2017).

  26. Taiwan FDA. file:///C:/Documents%20and%20Settings/station/My%20Documents/Downloads/ (accessed 26/Apr/2017).

  27. Poh J, Tam KT. Registration of similar biological products—Singapore’s approach. Biologicals. 2011;39(5):343–5.

    Article  PubMed  Google Scholar 

  28. National Pharmaceutical Control Bureau. Ministry of Health. Malaysia, “Drug registration guidance document (DRGA),” 2013, http://rr.mpc.gov.my/data/lic-legal-2013-12-24-06-40-33.pdf .

  29. http://www.biotechcorp.com.my/press-release/viropro-andoncobiologics-sign-emerging-markets-biosimilars-deal/ (accessed 18/ Apr/2017).

  30. Kadam V, Bagde S, Karpe M, Kadam V. A comprehensive overview on biosimialrs. Curr Protein Pept Sci. 2016;17(8):756–61.

    Article  CAS  PubMed  Google Scholar 

  31. Stevenson JG, Green L, pharmacovigilance, and patient safety: It’s all in the name.

Download references

Author information

Authors and Affiliations

  1. School of Medicine Kaohsiung Medical University, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou 1st Road, Kaohsiung, Taiwan

    Wen-Chan Tsai

Authors
  1. Wen-Chan Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wen-Chan Tsai.

Ethics declarations

Conflict of Interest

The author declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by author.

Additional information

This article is part of the Topical Collection on Biosimilars

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tsai, WC. Update on Biosimilars in Asia. Curr Rheumatol Rep 19, 47 (2017). https://doi.org/10.1007/s11926-017-0677-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-017-0677-1

Keywords

Search

Navigation